ONEPOINT Launches Next Generation Project Life Cycle Support with Planforge 22
28.2.2023 11:00:00 EET | Business Wire | Press release
ONEPOINT, a Gartner leader in adaptive project management and reporting, today launched its new Planforge platform — the successor to its hybrid PPM software ONEPOINT Projects. The first major release, Planforge 22, focuses on providing next-generation project life cycle support for agile and traditional projects and programs, including a new dynamic project closure process, modernized change requests, vastly enhanced standard reports, and support for RACI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005123/en/
Planforge 22 supports a new dynamic project closure, lessons learned, and more. (Graphic: Business Wire)
"Planforge is our next step in making hybrid PPM more accessible and powerful at the same time," said Gerald Aquila, founder and CEO of ONEPOINT. "By implementing best practices and lessons learned from hundreds of customer projects analyzed by leading PPM consultants, our software has distinctive built-in project management expertise that is unique in the market."
Dynamic Project Closure
Built around an always accessible project closure form, the new dynamic project closure process is the cornerstone of many practical enhancements to the new Planforge platform:
- 1–5-star ratings and comments for overall project success, each objective and KPI
- Post-project phase can be easily planned using to-dos
- Lessons learned can be added at any time
- Redesigned project closure PDF standard report is based on new capabilities
Lessons Learned
Besides playing an essential role in the new project closure process, lessons learned are real lightweight business objects that are fully reportable using Planforge's flexible report wizard.
"This is a major first step to preserving important project know-how and providing transparency and important learnings to all project stakeholders. Learning from past mistakes and applying successes to future projects is becoming a key success factor," stated Dieter Freismuth, CTO of ONEPOINT.
Modernized Change Requests
Another success factor is effective change request management. By completely redesigning the way change requests are entered and displayed in Planforge, ONEPOINT has managed to incorporate latest best practices while simplifying the user interface. ONEPOINT made change requests more dynamic by allowing project managers to delegate ownership and prioritize changes. Additionally, the Planforge platform now includes a built-in, customizable standard report for a change request.
RACI
Other enhancements include support for RACI, enabling project managers to improve their overview of team responsibilities for complex projects and programs.
Availability
Planforge is available for free for up to 4 users both as a cloud service and on-premises. ONEPOINT also provides different plans for extended connectivity, including a bidirectional integration to Atlassian's Jira. Sign up now at www.planforge.io.
About
ONEPOINT Projects empowers teams to make projects work. With its Planforge hybrid PPM software, ONEPOINT simplifies daily project work with a practical approach to project and portfolio management and enterprise agile planning. Recognized as a Gartner APMR leader, ONEPOINT builds on major standards such as IPMA, PMI, PRINCE2, and SAFe, enabling project-driven organizations to increase project and portfolio transparency, reduce time to market, and optimize resource utilization.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005123/en/
Contact information
ONEPOINT Projects GmbH
Kerstin Gaar
press@onepoint-projects.com
www.planforge.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom